Last updated on April 2016

A Phase 2b, Randomized, Double-blind, Double-dummy, Placebo-controlled, parallel-group, Dose-range-finding Study of Two Delayed Release Formulations of Linaclotide Adminsitered Orally for 12 Weeks to Patients with Irritable Bowel Syndrome with Constipation


Brief description of study

A Phase 2b, Randomized, Double-blind, Double-dummy, Placebo-controlled, parallel-group, Dose-range-finding Study of Two Delayed Release Formulations of Linaclotide Adminsitered Orally for 12 Weeks to Patients with Irritable Bowel Syndrome with Constipation

Detailed Study Description

To evaluate the safety, efficacy, and dose response of 2 different delayed release formulations of Linaclotide administered orally to patients with irritable bowel syndrome.

Clinical Study Identifier: TX143193

Contact Investigators or Research Sites near you

Start Over

Bobbi Duffy-Hidalgo APRN

Chase Medical Research, LLC
Waterbury, CT USA
  Connect »